Mechanism of action of memantine

Current Opinion in Pharmacology

Volumn 6, Issue 1 SPEC. ISS., 2006, Pages 61-67

  Johnson, Jon W ^a   Kotermanski, Shawn E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; AMANTADINE; AMYLOID BETA PROTEIN; DIZOCILPINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; KETAMINE; MAGNESIUM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR; PHENCYCLIDINE; PLACEBO; SEROTONIN RECEPTOR; SIGMA 1 OPIATE RECEPTOR;

ALZHEIMER DISEASE; BRAIN FUNCTION; CHANNEL GATING; CLINICAL TRIAL; DRUG BINDING; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; MEMBRANE STEADY POTENTIAL; MEMORY DISORDER; NERVE CELL EXCITABILITY; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 30844460987     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.09.007     Document Type: Review

References (62)

1. D. Lodge W. Danysz C.G. Parsons Ionotropic glutamate receptors as therapeutic targets 2002 FP Graham Pub Johnson City
2. G.C. Palmer Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies Curr Drug Targets 2 2001 241-271
3. S.A. Lipton Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults NeuroRx 1 2004 101-110
4. A. Witt N. Macdonald P. Kirkpatrick Memantine hydrochloride Nat Rev Drug Discov 3 2004 109-110
5. G.J. Kilpatrick G.S. Tilbrook Memantine. Merz Curr Opin Investig Drugs 3 2002 798-806
6. C.G. Parsons W. Danysz G. Quack Memantine is a clinically well tolerated N-methyl- d -aspartate (NMDA) receptor antagonist - a review of preclinical data Neuropharmacology 38 1999 735-767
7. A. Beister P. Kraus W. Kuhn M. Dose A. Weindl M. Gerlach The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease J Neural Transm Suppl 2004 117-122
8. S.A. Lipton Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders J Alzheimer's Dis 6 2004 S61-S74
9. J. Bormann Memantine is a potent blocker of N-methyl- d -aspartate (NMDA) receptor channels Eur J Pharmacol 166 1989 591-592
10. J. Kornhuber J. Bormann W. Retz M. Hubers P. Riederer Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex Eur J Pharmacol 166 1989 589-590
11. I. Bresink T.A. Benke V.J. Collett A.J. Seal C.G. Parsons J.M. Henley G.L. Collingridge Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells Br J Pharmacol 119 1996 195-204
12. C.G. Parsons R. Gruner J. Rozental J. Millar D. Lodge Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan) Neuropharmacology 32 1993 1337-1350
13. C.G. Parsons G. Quack I. Bresink L. Baran E. Przegalinski W. Kostowski P. Krzascik S. Hartmann W. Danysz Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo Neuropharmacology 34 1995 1239-1258
14. T.A. Blanpied F.A. Boeckman E. Aizenman J.W. Johnson Trapping channel block of NMDA-activated responses by amantadine and memantine J Neurophysiol 77 1997 309-323
15. H.S. Chen S.A. Lipton Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: Uncompetitive antagonism J Physiol 499 1997 27-46
16. A. Sobolevsky S. Koshelev Two blocking sites of amino-adamantane derivatives in open N-methyl- d -aspartate channels Biophys J 74 1998 1305-1319
17. A.I. Sobolevsky S.G. Koshelev B.I. Khodorov Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons J Physiol 512 1998 47-60
18. C.G. Parsons W. Danysz A. Bartmann P. Spielmanns T. Frankiewicz M. Hesselink B. Eilbacher G. Quack Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: In vitro and in vivo characterization Neuropharmacology 38 1999 85-108
19. K. Kashiwagi T. Masuko C.D. Nguyen T. Kuno I. Tanaka K. Igarashi K. Williams Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore Mol Pharmacol 61 2002 533-545
20. J. Kornhuber G. Quack Cerebrospinal fluid and serum concentrations of the N-methyl- d -aspartate (NMDA) receptor antagonist memantine in man Neurosci Lett 195 1995 137-139
21. R. Dingledine K. Borges D. Bowie S.F. Traynelis The glutamate receptor ion channels Pharmacol Rev 51 1999 7-61
22. G.E. Hardingham H. Bading The Yin and Yang of NMDA receptor signalling Trends Neurosci 26 2003 81-89
23. J.H. Krystal D.C. D'Souza I.L. Petrakis A. Belger R.M. Berman D.S. Charney W. Abi-Saab S. Madonick NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders Harv Rev Psychiatry 7 1999 125-143
24. P.F. Smith Therapeutic N-methyl- d -aspartate receptor antagonists: Will reality meet expectation? Curr Opin Investig Drugs 4 2003 826-832
25. M.A. Rogawski G.L. Wenk The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease CNS Drug Rev 9 2003 275-308
26. S.A. Lipton Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders J Alzheimers Dis 6 2004 S61-S74
27. H.P. Schmitt On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease Med Hypotheses 65 2005 259-265
28. W. Danysz C.G. Parsons J. Kornhuber W.J. Schmidt G. Quack Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies Neurosci Biobehav Rev 21 1997 455-468
29. M.E. Brau M. Dreimann A. Olschewski W. Vogel G. Hempelmann Effect of drugs used for neuropathic pain management on tetrodotoxin-resistant Na(+) currents in rat sensory neurons Anesthesiology 94 2001 137-144
30. B. Buisson D. Bertrand Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor Mol Pharmacol 53 1998 555-563
31. D. Oliver J. Ludwig E. Reisinger W. Zoellner J.P. Ruppersberg B. Fakler Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells Mol Pharmacol 60 2001 183-189
32. P.D. Maskell P. Speder N.R. Newberry I. Bermudez Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl- d -aspartate receptors Br J Pharmacol 140 2003 1313-1319
33. Y. Aracava E.F. Pereira A. Maelicke E.X. Albuquerque Memantine blocks alpha7 nicotinic acetylcholine receptors more potently than n-methyl- d -aspartate receptors in rat hippocampal neurons J Pharmacol Exp Ther 312 2005 1195-1205
34. P. Banerjee G. Samoriski S. Gupta Comments on "Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than N-methyl- d -aspartate receptors in rat hippocampal neurons" J Pharmacol Exp Ther 313 2005 928-929
35. E.S. Zakharova W. Danysz A.Y. Bespalov Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats Psychopharmacology (Berl) 179 2005 128-135
36. G. Rammes R. Rupprecht U. Ferrari W. Zieglgansberger C.G. Parsons The N-methyl- d -aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner Neurosci Lett 306 2001 81-84
37. Y.F. Sasaki T. Rothe L.S. Premkumar S. Das J. Cui M.V. Talantova H.K. Wong X. Gong S.F. Chan D. Zhang Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons J Neurophysiol 87 2002 2052-2063
38. S.M. Aamodt M. Constantine-Paton The role of neural activity in synaptic development and its implications for adult brain function Adv Neurol 79 1999 133-144
39. R.A. Nicoll R.C. Malenka Expression mechanisms underlying NMDA receptor-dependent long-term potentiation Ann N Y Acad Sci 868 1999 515-525
40. J.W. Olney Excitotoxicity, apoptosis and neuropsychiatric disorders Curr Opin Pharmacol 3 2003 101-109
41. I. Perez-Otano M.D. Ehlers Homeostatic plasticity and NMDA receptor trafficking Trends Neurosci 28 2005 229-238
42. H.S. Chen J.W. Pellegrini S.K. Aggarwal S.Z. Lei S. Warach F.E. Jensen S.A. Lipton Open-channel block of N-methyl- d -aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity J Neurosci 12 1992 4427-4436
43. G.A. Mealing T.H. Lanthorn C.L. Murray D.L. Small P. Morley Differences in degree of trapping of low-affinity uncompetitive N- methyl- d -aspartic acid receptor antagonists with similar kinetics of block J Pharmacol Exp Ther 288 1999 204-210
44. K.V. Bolshakov V.E. Gmiro D.B. Tikhonov L.G. Magazanik Determinants of trapping block of N-methyl-d-aspartate receptor channels J Neurochem 87 2003 56-65
45. H.S.V. Chen S.A. Lipton Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl- d -aspartate-gated channels J Pharmacol Exp Ther 314 2005 961-971
46. H. Yuan K. Erreger S.M. Dravid S.F. Traynelis Conserved structural and functional control of N-methyl- d -aspartate receptor gating by transmembrane domain M3 J Biol Chem 280 2005 29708-29716
47. J.W. Johnson A. Qian Interaction between channel blockers and channel gating of NMDA receptors Biologicheskie Membrany 19 2002 17-22
48. C.G. Parsons V.A. Panchenko V.O. Pinchenko A.Y. Tsyndrenko O.A. Krishtal Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine Eur J Neurosci 8 1996 446-454
49. T. Yamakura H. Mori H. Masaki K. Shimoji M. Mishina Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists Neuroreport 4 1993 687-690
50. F.R. Sharp M. Tomitaka M. Bernaudin S. Tomitaka Psychosis: Pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 24 2001 330-334
51. S.K. Sonkusare C.L. Kaul P. Ramarao Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope Pharmacol Res 51 2005 1-17
52. M.A. Rogawski Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents - toward an understanding of their favorable tolerability Amino Acids 19 2000 133-149
53. W. Danysz C.G. Parsons The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence Int J Geriatr Psychiatry 18 2003 S23-S32
54. J. Persson J. Hasselström A. Maurset I. Öye J.-O. Svensson O. Almqvist H. Scheinin L.L. Gustafsson O. Almqvist Pharmacokinetics and non-analgesic effects of S- and R-ketamine in healthy volunteers with normal and reduced metabolic capacity Eur J Clin Pharmacol 57 2002 869-875
55. I.S. Grant W.S. Nimmo J.A. Clements Pharmacokinetics and analgesic effects of i.m. and oral ketamine Br J Anaesth 53 1981 805-810
56. J.H. Krystal L.P. Karper J.P. Seibyl G.K. Freeman R. Delaney J.D. Bremner G.R. Heninger M.B. Bowers D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans Arch Gen Psychiatry 51 1994 199-214
57. U. Busto R. Bendayan E.M. Sellers Clinical pharmacokinetics of non-opiate abused drugs Clin Pharmacokinetics 16 1989 1-26
58. K.V. Bolshakov K.H. Kim N.N. Potapjeva V.E. Gmiro D.B. Tikhonov P.N. Usherwood I.R. Mellor L.G. Magazanik Design of antagonists for NMDA and AMPA receptors Neuropharmacology 49 2005 144-155
59. T.A. Blanpied R.J. Clarke J.W. Johnson Amantadine inhibits NMDA receptors by accelerating channel closure during channel block J Neurosci 25 2005 3312-3322
60. G.A. Mealing T.H. Lanthorn D.L. Small R.J. Murray K.C. Mattes T.M. Comas P. Morley Structural modifications to an N-methyl- d -aspartate receptor antagonist result in large differences in trapping block J Pharmacol Exp Ther 297 2001 906-914
61. A.I. Sobolevsky C. Beck L.P. Wollmuth Molecular rearrangements of the extracellular vestibule in NMDAR channels during gating Neuron 33 2002 75-85
62. A. Qian J.W. Johnson Channel gating of NMDA receptors Physiol Behav 77 2002 577-582